Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07624396

Association Between Circulating BDNF Levels and Cardioembolic Strokes in Patients Treated for Ischemic Stroke

Atrial fibrillation (AF) is associated with serious complications, including embolic strokes, heart failure, and mortality. Disruption of normal blood flow in the atrium, particularly in the context of an endocardium predisposed to thrombosis, increases the risk of thrombus formation. Once dislodged from the atrial cavity and traveling to the cerebral arteries, these thrombi can cause a cardioembolic stroke. The main risk factors for atrial cardiomyopathy (ACM) and AF are metabolic syndrome and aging.

ACM is a condition that is difficult to diagnose because it is not clearly defined, except through histological analysis. Guided by the results of our experimental approaches, the investigators aim to address this challenge by examining ACM through the lens of one of its complications: cardioembolic stroke. BDNF (Brain-Derived Neurotrophic Factor) is a neurotrophic factor involved in inflammatory and metabolic processes that may play a key role in the development of these complications.

This study explores the association between circulating levels of BDNF and the morphological and metabolic characteristics of ACM, as assessed by cardiac and brain imaging studies

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals who provided informed consent
  • Diagnosis of acute ischemic stroke confirmed by brain imaging (CT or MRI)
  • Patient admitted to the USINV of the Department of General, Vascular, and Degenerative Neurology at the Dijon Bourgogne University Hospital during the inclusion period
  • Underwent a combined cardiac and brain CT scan within 24 hours of admission for stroke

Exclusion criteria

  • A person subject to a legal protective measure (guardianship, conservatorship)
  • A person subject to a judicial safeguard measure
  • A pregnant woman, a woman who has recently given birth, or a breastfeeding woman
  • An adult who is legally incapacitated or unable to give consent,
  • A minor

Treatment and study plan

Circulating BDNF levels measured via blood sample

Biological

Diagnosis of cardioembolic stroke according to the TOAST13 classification, adjudicated with a blinded review of biomarker data by the treating of a neurologist upon the patient' s hospital discharge

Primary outcomes

  1. Diagnosis of cardioembolic stroke according to the TOAST classification, adjudicated with a blinded review of biomarker data by the treating of a neurologist upon the patient' s hospital discharge.

    Time frame: At hospital discharge (approximately 5 to 10 day after admission)

Study contacts

Contact information is provided by the study sponsor or research team.

Charles GUENANCIA, Pr

CONTACT

[email protected]

03.80.29.56.23

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire Dijon

Other

Registry information

Acronym: METAPROFIL 1

Important dates

Study start
2026
Primary completion
2031
Study completion
2031
First posted
Jun 3, 2026
Registry last updated
Jun 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.